Don’t overlook management of medications in infection battle
By John Hall
McKnight’s Long Term Care News
Many once-waning yet still-debilitating infections are rising in numbers again, erasing some of the gains made fighting multidrug resistant organisms.
Because nursing home staff were so focused on a vertical approach toward fighting the pandemic, epidemiologists are reporting increases in infections such as MRSA and Candida auris, observed Medline Medical Science Liaison Caryn Arnold.
“Just because you aren’t looking for all those multidrug-resistant organisms we were trying to focus on prior to COVID-19 does not mean they are not there,” added Deb Burdsall, Ph.D., of Baldwin Hills Solutions, LLC.
Even maladies like chlamydia, gonorrhea and syphilis are on the rise because events such as routine testing and elective surgeries were either postponed or unavailable, said Mary Madison, top clinical consultant for LTC/senior living at Briggs Healthcare. The pandemic has hindered medication management efforts to contain similarly dangerous infections.
“In some ways, the fight against COVID-19 has diverted our attention from some very key priorities,” said Chad Worz, PharmD, CEO of the American Society of Consultant Pharmacists. “From an infection control perspective, things like sliding scale insulin, the use of medications that must be administered three and four times a day, and polypharmacy in general become targets to reduce the potential transmission of the virus between staff and residents.”
Meanwhile, COVID-related medication management and attendant vaccines, monoclonal antibodies, and oral antivirals will continue to be prominent concerns in 2022, said Cristina Crawford, spokeswoman for the American Health Care Association/National Center for Assisted Living.
Going forward, access to COVID treatments across all senior living settings will be critical, noted Alan Rosenbloom, president and CEO of the Senior Care Pharmacy Coalition.
Worz believes a priority coming out of the pandemic should include a renewed effort “to ensure we are balancing the non-pharmaceutical interventions with any needed medications.”
This article first appeared on McKnight’s Long Term Care News. You can read the original here.
Recent Posts
-
Rosenbloom: Curb PBMs’ power
Despite the purported value of pharmacy benefit managers (PBMs), drug prices remain unaffordable for many Americans (“Prescription drug pricing reform must rein in pharmacy benefit managers,” Web, Oct. 18). As middlemen between the manufacturers, pharmacies and consumers, PBMs are notorious for abusive business practices that impact both patients’ wallets and their access to prescription drugs, while gouging unaffiliated pharmacies.
-
Prescription Drug Middleman Potentially Profiting off Veterans
One of the three dominant U.S. pharmacy benefit managers (PBMs)—the middlemen that handle the vast majority of prescription drug plans in the United States—has instituted a scheme that has left roughly 400,000 active-duty and retired military households scrambling for a new pharmacy provider within the next week. Critics say the maneuver is a naked attempt by Express Scripts, the Cigna-owned PBM, to steer beneficiaries toward its own market-leading mail-order pharmacy.
-
The surprising group that will be hit hard by drug pricing reform
By Rachel CohrsSTAT Obviously, pharmaceutical companies are upset that they’re going to lose money from Medicare under Democrats’ new drug pricing law. But there’s another, less obvious group that’s concerned as well — long-term care pharmacies that serve almost entirely Medicare patients, and dispense the drugs that will likely enter the price negotiation program first. […]
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.